Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening

Lignende værker

• The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
  af: Ejegod, Ditte, et al.
  Udgivet: (2016)
• Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II(+) detection rates
  af: Rozemeijer, Kirsten, et al.
  Udgivet: (2015)
• Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework
  af: Bonde, Jesper Hansen, et al.
  Udgivet: (2020)
• Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark
  af: Rebolj, Matejka, et al.
  Udgivet: (2015)
• Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study
  af: Rozemeijer, Kirsten, et al.
  Udgivet: (2017)